Scholar Rock Holding Corporation (SRRK)

13,86 +0,51 (+3,82%) In data: 11:26AM EDT. Mercato aperto.

Scholar Rock Holding Corporation

301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 150

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jay Thomas Backstrom M.D., M.P.H.	President, CEO & Director	1,07M	N/D	1955
Mr. Edward H. Myles MBA	CFO, COO & Treasurer	720,79k	N/D	1972
Ms. Tracey M. Sacco M.B.A.	Chief Commercial Officer	548,86k	N/D	1976
Mr. Mo Qatanani Ph.D.	Chief Scientific Officer	N/D	N/D	1973
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	N/D	N/D	N/D
Ms. Junlin Ho J.D.	General Counsel & Corporate Secretary	563,73k	N/D	1979
Ms. Caryn Parlavecchio	Chief Human Resources Officer	N/D	N/D	1972
Ms. Lisa Amaya Price	Senior Vice President of Human Resources	N/D	N/D	N/D
Ms. Erin Moore	Senior Vice President of Finance	N/D	N/D	1975
Mr. Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Scholar Rock Holding Corporation al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.